GeoVax Labs GOVX
NASDAQ GOVX
$2.16 -0.52 (-19.28%)
At close: Nov 11, 2026 · 4:00 PM EST

GeoVax Labs (GOVX) Price to Sales (2020 - 2026)

Updated

GeoVax Labs' Price to Sales came in at 6.80 for Q2 2026, down 87.9% from 56.12 a year earlier.

Analysis

GeoVax Labs (GOVX) Price to Sales (2020 - 2026) Analysis & Trends

For FY2025, GeoVax Labs' Price to Sales was 1.65, down 98.0% from FY2024.

  • Going back by year, Price to Sales was 80.99 in FY2024, 3279.21 in FY2022 (+118.9%) and 1498.20 in FY2021.
  • The five-year range for quarterly Price to Sales is 1.65 (Q4 2025) to 3279.21 (Q4 2022).
  • The fastest year-over-year change in Price to Sales over five years came in Q4 2022 (growth of 118.9%), and the weakest in Q4 2025 (a decline of 98.0%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 GeoVax Labs 502,172.77 -12.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 3.25
Dec 31, 2025 1.65
Sep 30, 2025 71.50
Jun 30, 2025 56.12
Mar 31, 2025 65.59
Dec 31, 2024 80.99
Sep 30, 2024 124.88
Jun 30, 2024 672.57
Dec 31, 2022 3,279.21
Sep 30, 2022 2,911.55
Jun 30, 2022 953.36
Mar 31, 2022 573.20
Dec 31, 2021 1,498.20
Sep 30, 2021 1,459.76
Jun 30, 2021 922.77
Mar 31, 2021 567.75
Dec 31, 2020 64.12
Sep 30, 2020 33.93
API Access

GeoVax Labs Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=GOVX&period=max&api_key=YOUR_API_KEY